bionovo inc

Bionovo, Inc. (Nasdaq: BNVID) 56.6% HIGHER; announced that the U.S. FDA accepted the Company's Chemistry, Manufacturing and Controls plan for its lead drug candidate, Menerba®, in a Type "B" or "End of Phase 2" meeting.

With this designation, the decisions and agreements are now considered binding on the Company and the FDA.

TerreStar (Nasdaq: TSTR) 37.1% HIGHER; the stock is continuing higher today; shares surged 17% on Monday amid news that AT&T (NYSE: T) has launched its SAM Service on TerreStar's GENUS Dual-Mode smartphone.

Bionovo, Inc. (NASDAQ: BNVI) 26.3% HIGHER; announced today the publication of results from its study on the anti-tumor mechanism of BN107.

The results of the study, published in the International Journal of Cancer, describe the potential molecular mechanisms mediating the selective pro-apoptotic (cell death) effect induced by BN107 on estrogen receptor negative breast cancer cells. Click here to see the results.

AspenBio Pharma, Inc.

Bionovo, Inc. (Nasdaq: BNVI) 93.8% HIGHER; today announced positive results from the Phase 1B clinical trial of Bezielle (formerly BZL101), their lead drug candidate for advanced breast cancer.

In the trial, Bezielle showed an excellent safety and tolerability profile, and also showed promising indications of efficacy in a difficult-to-treat population. Click here for the full report.

WPT Enterprises, Inc.